BiotechTube
Myria Biosciences

Myria Biosciences

Basel, Switzerland· Est.
myria.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Myria Biosciences, founded in 2019 and based in Basel, Switzerland, is a private, pre-clinical stage biotech company operating at the intersection of AI, machine learning, and microbiome/synthetic biology. The company's core innovation is the GEMMS (Genetically Engineered Modular Molecule Scaffolds) platform, which uses AI to design and microbes to produce millions of novel, natural product-like molecules weekly for drug discovery. Myria aims to address challenging disease targets by accessing chemical space beyond traditional methods, positioning itself in the competitive AI-driven drug discovery landscape with a unique biological production angle.

AI / Machine LearningMicrobiome

Technology Platform

GEMMS (Genetically Engineered Modular Molecule Scaffolds) Platform: An integrated AI-driven design, synthetic biology production, and high-throughput analytics platform for discovering novel natural product-inspired therapeutics.

Opportunities

Myria has the opportunity to tap into the vast, proven chemical space of natural products while using AI to overcome traditional discovery limitations, potentially leading to first-in-class drugs for undruggable targets.
Its location in Basel provides unparalleled access to potential pharmaceutical partners and investors.
Successfully demonstrating its platform could position it as a leader in the convergence of AI and synthetic biology for drug creation.

Risk Factors

The company faces significant technical risk in integrating complex AI and synthetic biology workflows into a reliable, high-output discovery engine.
As a pre-revenue private company, it is vulnerable to shifts in biotech funding sentiment and must continuously achieve milestones to secure financing.
It operates in the highly competitive AI-drug discovery landscape, where many players are also racing to validate their platforms.

Competitive Landscape

Myria competes in the broad AI for drug discovery market against pure-play AI companies (e.g., Exscientia, Insilico Medicine) and large biopharma internal efforts. Its key differentiation is the closed-loop use of engineered microbes for biological synthesis and testing, a approach shared by a smaller subset of synbio-focused players. It must prove its integrated platform is more productive and effective than competitors using more traditional chemistry methods.

More companies in Microbiome Therapeutics →More companies in Switzerland →